Welcure Drugs Hits Upper Circuit as Telexcell Trade Plans 25% Strategic Stake at ₹20 Per Share

New Delhi, September 3, 2025: Welcure Drugs & Pharmaceuticals Ltd.’s share price is witnessing strong investor demand today. As of 2:35 PM, the shares have hit the 5% upper circuit and are up by 0.43 points to trade at ₹9.22. Until now, the shares have traded within a range of ₹9.22 and ₹8.40. The traded volume stands at 28.33 lakh shares, and the market cap stands at ₹99 crore. The significant rally comes after the company announced that it has received a Letter of Intent (LOI) with Singapore-based Telexcell Trade PTE LTD for a proposed strategic equity investment of up to 25% in the company.

Welcure Drugs & Pharmaceuticals Ltd. is an Indian pharmaceutical and healthcare company that was established in 1992. Its headquarters are in New Delhi, India. It is listed on the BSE with the code 524661.

Telexcell Trade PTE LTD to Acquire 25% Stake in Welcure Drugs at ₹20 Per Share in All-Cash Deal

The terms of the transaction include an equity investment from Telexcell Trade PTE LTD, Singapore, to buy a 25% stake in Welcure Drugs & Pharmaceuticals Ltd. The deal is proposed to be executed at ₹20 per share, which is a hefty premium compared to the current share price of ₹9.22. The deal will be executed in all cash, but is subject to due diligence by Telexcell Trade.

Strategic Investment Aims to Boost Welcure Drugs’ Global Pharma and Chemical Market Presence Within 90 Days

The strategic rationale behind the deal is to strengthen Welcure Drugs’ global footprint in pharma & chemical exports. Both parties plan to execute the translation within 90 days of the LOI. “The proposed investment from Telexcell Trade reflects confidence in Welcure’s business model and will enable us to expand our footprint across emerging markets in pharmaceuticals and chemicals,” said Chintan Didawala Ganpat, Director, Welcure Drugs & Pharmaceuticals Ltd.

Th͏e a͏nnounce͏ment ͏of Telexcell͏ Trade’s prop͏o͏sed 25% s͏take in Wel͏c͏ure Drugs & Pharmace͏uticals Ltd highl͏ights a key͏ strategic step for the comp͏any. The ͏all͏-cash d͏eal a͏t ₹20 per share, p͏lanned ͏to complet͏e͏ within 9͏0 d͏ays, is designed to ͏streng͏then We͏lcure’s ͏inte͏rnationa͏l͏ footprin͏t in p͏harmace͏uticals and chem͏icals, supporting i͏ts ͏broa͏de͏r growth and expansio͏n͏ objectives in ͏global ͏markets.

REF: https://www.bseindia.com/xml-data/corpfiling/AttachLive/db2db08a-9ee0-4500-85a8-3d9227668329.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations